Adagene, Inc.

NASDAQ:

ADAG

Adagene, Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its proprietary pipeline is comprised of novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

Key Facts

Auditor

Public Listing

Domicile

HQ/Management

Location of Key Operations

IR Contact

PricewaterhouseCoopers Zhong Tian LLP

IPO (February 9, 2021)

Cayman Islands

Jiangsu, China

Raymond Tam, Internal

86-8777-3626

Analyst Coverage

Latest News